Compare Abbott Laboratories (ABT) vs General Motors Company (GM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs General Motors Company — how do they compare? Abbott Laboratories trades at $95.23 (market cap $166.94B), while General Motors Company trades at $75.61 (market cap $68.55B). The key difference: Abbott Laboratories is far larger — about 2.4× General Motors Company's market cap, and Abbott Laboratories pays the higher dividend (2.63%). Which is the better fit depends on your goals.
| ABT | GM | |
|---|---|---|
Market Cap | $166.94B | $68.55B |
Sector | Health | Consumer Cyclical |
52-Week High | $136.62 | $86.38 |
52-Week Low | $82.57 | $48.89 |
Enterprise Value | $193.69B | $171.89B |
Dividend Yield | 2.63% | 0.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
General Motors (GM) trades at $76.03, showing minimal daily movement with a 0.04% gain. The stock presents a mixed technical picture with bearish moving averages but oversold RSI conditions. Fundamentally, GM demonstrates strong cash flow generation ($26.9B operating cash flow in 2025) and consistent earnings beats, though profit margins remain thin at 1.38%. Recent news highlights strategic partnerships with Micron Technology and ongoing EV transition challenges.
GM offers value with attractive valuation multiples (P/S: 0.4x, P/B: 1.12x) and analyst consensus pointing to 31% upside potential. However, investors face risks from cyclical auto demand, margin pressure, and high debt levels. The company's scale and cash flow strength provide stability, but execution on EV strategy remains critical for long-term growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About General Motors Company
General Motors Co. emerged from the bankruptcy of General Motors Corp. (old GM) in July 2009. GM has eight brands and operates under four segments: GM North America, GM International, Cruise, and GM Financial. The United States now has four brands instead of eight under old GM. The company lost its U.S. market share leader crown in 2021 with share down 280 basis points to 14.6%, but we expect GM to reclaim the top spot in 2022 as 2021 suffered from the chip shortage. GM Financial became the company's captive finance arm in October 2010 via the purchase of AmeriCredit.
Read more on GM →
